These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 16419116)

  • 1. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
    Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
    Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
    Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
    Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
    Liaw YF; Chien RN; Yeh CT
    Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Joh JW; Lee HH; Park JW; Lee DH; Yoo BC; Lee KW; Kim SJ
    Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.